HUP0201791A3 - The use of escitalopram for treatment of neurotic disorders - Google Patents

The use of escitalopram for treatment of neurotic disorders

Info

Publication number
HUP0201791A3
HUP0201791A3 HU0201791A HUP0201791A HUP0201791A3 HU P0201791 A3 HUP0201791 A3 HU P0201791A3 HU 0201791 A HU0201791 A HU 0201791A HU P0201791 A HUP0201791 A HU P0201791A HU P0201791 A3 HUP0201791 A3 HU P0201791A3
Authority
HU
Hungary
Prior art keywords
escitalopram
treatment
neurotic disorders
neurotic
disorders
Prior art date
Application number
HU0201791A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0201791(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of HUP0201791A2 publication Critical patent/HUP0201791A2/hu
Publication of HUP0201791A3 publication Critical patent/HUP0201791A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
HU0201791A 1999-07-08 2000-07-07 The use of escitalopram for treatment of neurotic disorders HUP0201791A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08

Publications (2)

Publication Number Publication Date
HUP0201791A2 HUP0201791A2 (en) 2002-10-28
HUP0201791A3 true HUP0201791A3 (en) 2005-02-28

Family

ID=8099796

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201791A HUP0201791A3 (en) 1999-07-08 2000-07-07 The use of escitalopram for treatment of neurotic disorders

Country Status (38)

Country Link
US (6) US7271194B2 (enExample)
EP (4) EP1440691A3 (enExample)
JP (1) JP4773011B2 (enExample)
KR (1) KR100604176B1 (enExample)
CN (1) CN1198610C (enExample)
AR (1) AR021155A1 (enExample)
AT (1) ATE339955T1 (enExample)
AU (6) AU782514B2 (enExample)
BG (4) BG110467A (enExample)
BR (1) BR0011578A (enExample)
CA (4) CA2687392A1 (enExample)
CL (3) CL2008003941A1 (enExample)
CO (1) CO5190674A1 (enExample)
CY (1) CY1105806T1 (enExample)
CZ (1) CZ200270A3 (enExample)
DE (1) DE60030861T2 (enExample)
DK (1) DK1200081T3 (enExample)
EA (1) EA006555B1 (enExample)
ES (1) ES2272298T3 (enExample)
HK (1) HK1048069B (enExample)
HR (1) HRP20010820A2 (enExample)
HU (1) HUP0201791A3 (enExample)
IL (5) IL146131A0 (enExample)
IS (1) IS6137A (enExample)
ME (2) MEP2508A (enExample)
MX (1) MXPA01011626A (enExample)
MY (1) MY143278A (enExample)
NO (4) NO329021B1 (enExample)
PL (1) PL352030A1 (enExample)
PT (1) PT1200081E (enExample)
SI (1) SI1200081T1 (enExample)
SK (1) SK82002A3 (enExample)
TR (4) TR200402276T2 (enExample)
TW (1) TWI232101B (enExample)
UA (1) UA77645C2 (enExample)
WO (1) WO2001003694A1 (enExample)
YU (1) YU78701A (enExample)
ZA (1) ZA200108856B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
BR0113011A (pt) * 2000-07-21 2003-07-01 Lundbeck & Co As H Novos compostos e sua utilização como inibidores de transporte de glicina; composição farmacêutica e método do tratamento
CN1509169A (zh) * 2001-05-01 2004-06-30 H��¡�±������޹�˾ 对映体纯艾司西酞普兰的用途
ES2233842T3 (es) 2001-07-31 2005-06-16 H. Lundbeck A/S Composicion cristalina que contiene escitalopram.
WO2004004721A1 (en) * 2002-07-08 2004-01-15 University Of Florida Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
MXPA05005772A (es) * 2002-12-23 2005-08-16 Lundbeck & Co As H Bromhidrato de escitalopram y un metodo para su preparacion.
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP2272514A1 (en) * 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2625835A1 (en) 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (enExample) 1965-03-18
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4436874A (en) 1981-11-19 1984-03-13 Societe D'expansion Scientifique "Expansia" Acrylic copolymers and their use in solid phase peptide synthesis
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
DK213290D0 (da) 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
WO1993009769A1 (en) 1991-11-15 1993-05-27 Sepracor, Inc. Methods and compositions utilizing pure s(+) isomer fluoxetine
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1996024353A1 (en) * 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) 1995-04-27 1995-04-27 Astra Ab A new combination
DK0759299T3 (da) 1995-08-16 2000-08-07 Lilly Co Eli Potensering af serotoninrespons
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
UA62984C2 (en) * 1997-11-11 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
DK0957099T3 (da) * 1998-04-15 2003-03-17 Pfizer Prod Inc Heterocykliske carboxamider
JP2002519321A (ja) * 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
DE69935331T2 (de) 1998-07-13 2007-10-31 NPS Pharmaceuticals, Inc., Salt Lake City Verfahren und verbindungen zur behandlung der depression
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
CA2337507A1 (en) 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition for treatment of stress
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SK285719B6 (sk) * 1998-10-20 2007-07-06 H. Lundbeck A/S Spôsob prípravy citalopramu a medziprodukty
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
EP1173431B2 (en) * 1999-04-14 2009-08-26 H. Lundbeck A/S Method for the preparation of citalopram
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
EP1276478A2 (en) 2000-04-24 2003-01-22 ARYx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
CN1509169A (zh) * 2001-05-01 2004-06-30 H��¡�±������޹�˾ 对映体纯艾司西酞普兰的用途

Also Published As

Publication number Publication date
IL170193A (en) 2010-04-29
US20070276035A1 (en) 2007-11-29
HRP20010820A2 (en) 2003-08-31
BG110468A (en) 2010-01-29
CA2687392A1 (en) 2001-01-18
US20040029957A1 (en) 2004-02-12
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
AU2005202686A1 (en) 2005-07-14
UA77645C2 (en) 2007-01-15
US20020086899A1 (en) 2002-07-04
CN1198610C (zh) 2005-04-27
HK1048069A1 (en) 2003-03-21
CL2008003939A1 (es) 2009-06-05
HK1048069B (zh) 2005-12-16
AU782514B2 (en) 2005-08-04
NO329021B1 (no) 2010-07-26
TR200402277T2 (tr) 2005-01-24
BG106279A (bg) 2002-08-30
AU2005202686B2 (en) 2009-01-15
IS6137A (is) 2001-10-30
IL146131A (en) 2007-02-11
ME00032B (me) 2010-02-10
AR021155A1 (es) 2002-06-12
BR0011578A (pt) 2002-03-26
IL170192A (en) 2010-04-29
WO2001003694A1 (en) 2001-01-18
DE60030861T2 (de) 2007-05-03
SK82002A3 (en) 2002-07-02
EP1200081A1 (en) 2002-05-02
AU2008264182A1 (en) 2009-01-29
NO20100334L (no) 2002-01-07
ES2272298T3 (es) 2007-05-01
CZ200270A3 (cs) 2002-04-17
EP1440689A2 (en) 2004-07-28
CY1105806T1 (el) 2011-02-02
CA2687394A1 (en) 2001-01-18
JP4773011B2 (ja) 2011-09-14
YU78701A (sh) 2004-03-12
EP1440690A2 (en) 2004-07-28
BG110466A (en) 2010-01-29
PT1200081E (pt) 2007-01-31
MY143278A (en) 2011-04-15
BG110467A (en) 2010-01-29
ATE339955T1 (de) 2006-10-15
ZA200108856B (en) 2002-12-24
CA2373757A1 (en) 2001-01-18
MXPA01011626A (es) 2002-06-04
TR200200014T2 (tr) 2002-05-21
CO5190674A1 (es) 2002-08-29
CN1360501A (zh) 2002-07-24
TR200402275T2 (tr) 2005-03-21
CL2008003938A1 (es) 2009-05-22
US20040029956A1 (en) 2004-02-12
EP1440690A3 (en) 2004-08-18
EP1440689A3 (en) 2004-08-25
TR200402276T2 (tr) 2005-01-24
US20040029958A1 (en) 2004-02-12
EA006555B1 (ru) 2006-02-24
AU2005202685B2 (en) 2009-01-15
US7265151B2 (en) 2007-09-04
TWI232101B (en) 2005-05-11
CA2373757C (en) 2010-01-05
IL146131A0 (en) 2002-07-25
AU2008264188A1 (en) 2009-05-07
HUP0201791A2 (en) 2002-10-28
AU2005202685A1 (en) 2005-07-14
AU5806100A (en) 2001-01-30
US7271194B2 (en) 2007-09-18
NO20100335L (no) 2002-01-07
PL352030A1 (en) 2003-07-28
EP1440691A3 (en) 2004-08-25
US20050101665A1 (en) 2005-05-12
US6960613B2 (en) 2005-11-01
DK1200081T3 (da) 2006-12-27
CA2687396A1 (en) 2001-01-18
EP1200081B1 (en) 2006-09-20
MEP2508A (xx) 2010-02-10
NO20100333L (no) 2002-01-07
AU2005202684A1 (en) 2005-07-14
EP1440691A2 (en) 2004-07-28
NO20020062D0 (no) 2002-01-07
KR100604176B1 (ko) 2006-07-25
AU2005202684B2 (en) 2009-01-15
EA200200137A1 (ru) 2002-06-27
CL2008003941A1 (es) 2009-05-22
KR20020015346A (ko) 2002-02-27
DE60030861D1 (de) 2006-11-02
IL170194A (en) 2010-05-31
JP2003504332A (ja) 2003-02-04

Similar Documents

Publication Publication Date Title
GB0007193D0 (en) Treatment of movrmrnt disorders
GB0010669D0 (en) Compositions for treatment of disorders of the oesophagus
HUP0400914A3 (en) Methods of treatment of mitochondrial disorders
EP1063990A4 (en) THERAPY FOR ESTROGEN RELATED DISORDERS
IL153425A0 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
HUP0201791A3 (en) The use of escitalopram for treatment of neurotic disorders
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
GB9926968D0 (en) Treatment of neurological disorders
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
IL140540A0 (en) Treatment of anxiety disorders
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
GB0010496D0 (en) Treatment of conditions of the central nervous system
GB9924942D0 (en) Treatment of movement disorders
GB9816355D0 (en) The treatment of viral disorders
GB9816353D0 (en) The treatment of viral disorders
GB9923551D0 (en) Treatment of neuropsychiatric disorders
HK1055908A (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
GB9815188D0 (en) Treatment of skin disorders
GB9918058D0 (en) Compound for treatment of gi disorders
GB0003228D0 (en) Treatment of GI disorders
GB0017951D0 (en) Treatment of movement disorders

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees